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Metabolic syndrome is defined as the clustering in an individual of several metabolic abnormalities associated with insulin
resistance, type 2 diabetes, and obesity, in which low-grade chronic inflammatory activity is commonly observed. Part of the
European Project PlantLIBRA is concerned with methods to assess the benefits of plant food supplements (PFSs) in countering
inflammatory activity and metabolic syndrome. This paper summarizes the current methods used for benefit assessment of PFS,
taking into consideration only in vitro, in silico, and clinical methodologies used to investigate the anti-inflammatory properties
of plants. No in silico studies (using computer simulation) related to metabolic syndrome were found; these methods appear to
be used exclusively for identifying or testing potentially effective compounds in drug development. Most in vitromethods for the
assessment of beneficial effects of botanicals or plant food supplements in diabetes were based on a quantitative polymerase chain
reaction (PCR), whereas the preferred kind of clinical study was the double-blind randomized controlled clinical trial. Only two
parameters were observed to change after treatment with botanicals in both in vitro and in vivo studies: interleukin-6 and tumour
necrosis factor-𝛼, and these biomarkers should be carefully considered in future studies for PFS benefit assessment.
1. Introduction
Metabolic syndrome (MS) defines the clustering in an indi-
vidual of multiple metabolic abnormalities [1]. World Health
Organization and programs including the National Choles-
terol Education Program (NCEP) and Adult Treatment Pro-
gram III (ATP III) have now agreed [2, 3] to consider MS as a
disease characterized by five traits: (1) increased abdominal
girth, (2) low levels of high-density lipoprotein cholesterol
(HDL-C), (3) hypertriglyceridemia, (4) hypertension, and (5)
fasting hyperglycemia. A low-grade chronic inflammatory
activity is commonly observed in metabolic diseases such as
obesity and type 2 diabetes (T2D).
A major shortcoming of current definitions of MS is the
lack of inclusion of measures of a proinflammatory state and
oxidative stress [4, 5]. The multicenter Insulin Resistance
Atherosclerosis Study had shown a linear relation between
the inflammatory marker C-reactive protein (CRP) and a
number of metabolic disorders [6]. Other proinflammatory
markers known to increase in patients with MS include
fibrinogen [2], cytokines such as interleukin-6 (IL-6), and
tumour necrosis factor-𝛼 (TNF-𝛼).
Type 2 diabetes (T2D) is considered an MS-related
disease and an inflammatory disease. As with MS, patients
with T2D show higher levels of circulating CRP, fibrinogen,
plasminogen activator inhibitor (PAI), and proinflammatory
cytokines such as interleukin-1𝛽 (IL-1𝛽) and IL-6. Circulating
levels of IL-18 have been reported to be elevated in subjects
with the metabolic syndrome and closely associated with the
biomarkers of the syndrome to predict cardiovascular events
and mortality in populations affected by MS-related diseases
[7]. In patients with T2D, metabolic stress promotes insulin
resistance and activation of IkB kinase-𝛽 (IKK𝛽) and JUN
N-terminal kinase (JNK), which suggests that these kinases
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have key roles in the pathogenesis of this disease [8]. IKK𝛽
activates nuclear factor-𝜅B (NF-𝜅B) which induces expres-
sion of NF-𝜅B-dependent genes such as proinflammatory
cytokines (e.g., TNF𝛼 and IL-1𝛽), so that the suppression
of this transcription factor could reduce metabolic disorders
and the complications occurring in diabetes (retinopathy,
nephropathy, and neuropathy) [8].
In the last 10 years, the link between inflammation
and nutrition has become increasingly apparent [8–10]. It
has been shown that excessive macronutrient intake can
contribute to the inflammatory response occurring in MS
[11], whereas some dietary polyphenols are able to reduce the
incidence ofMS, including diabetes [12].Many of themetabo-
lites occurring in plants are now recognized as useful for the
maintenance of human health, hence the recommended use
of plant food supplements (PFSs). A methodology for the
safety assessment of botanicals has been promoted by EFSA
(European Food Safety Authority), but major bottlenecks
remain in its implementation.
The European Project PlantLIBRA (acronym for plant
food supplements: levels of intake, benefit, and risk assess-
ments) aims to promote the safe use of PFS or botanicals
and the measurement of the risk/benefit ratio related to their
consumption. Part of the project is devoted to the discovery
of methods for the evaluation of the benefits of PFS and
their application and validation. The first step was to review
the evidence for PFS benefit in epidemiological, clinical, and
intervention studies, in particular the value of PFS as anti-
inflammatory agents [13, 14].
The aim of the present paper was to identify the in
vitro and in vivo methods that can detect a decrease of the
inflammatory biomarkers that play a key role in metabolic
syndrome and diabetes.
2. Methods
2.1. Source and Search Strategy. The following databases were
searched electronically to identify relevant articles published
up to September 2011: PubMed/Medline, SciFinder Scholar,
and Cochrane Library. Search limits were in vitro, in silico,
clinicalmethodologies, and the European languages, without
limits of year of publication.
A search strategy was developed for each electronic
database using specific medical subject heading (MeSH)
terms (e.g., inflammation mediators, C reactive protein CRP,
and metabolic X syndrome) in addition to relevant text
keywords (plant extract, plant preparation, methods, and
analytical approaches).
The same MeSH terms were used in the T2D area and in
theMS area to search for inflammatory biomarkers and plant
extracts, and the specific terms diabetes mellitus, noninsulin-
dependent OR diabetes mellitus, and type II were combined
with relevant keywords (plant extract, plant preparation,
methods, and analytical approaches).
Titles and abstracts of retrieved citations were first
screened to identify publications reporting in vivo methods
developed in humans, in vitro and in silico methods used
in inflammation conditions related to MS or diabetes. Ani-
mal studies were not considered since PlantLIBRA neither
uses nor promotes in vivo experiments on animals. Other
exclusion criteria were the use of plant ingredients for home-
opathy, topical use, aerosol/inhalation, and hygiene products.
Reviews, commentaries, and patents were also discarded.
3. Results and Discussion
The search by title and abstract retrieved 46 papers for MS
and 68 for diabetes. After removal of duplicates and appli-
cation of the inclusion/exclusion criteria, the total number
of papers was 43. Papers were also rejected if they were not
in a European language. In silico methods for assessing PFS
benefit in MS-related diseases were not found. All the studies
selected for diabetes were related to T2D.
3.1. Metabolic Syndrome Studies. Neither in silico nor in vitro
studies for assessing inflammation in metabolic syndrome
were found. Although diabetes is one of the features of
MS, the methods related to diabetes have been considered
separately from those relating to MS, because of the com-
plexity of the metabolic syndrome, which includes several
alterations of metabolic conditions not specifically associated
with diabetes.
3.1.1. In Vivo Methods. Table 1 reports the in vivo methods
used in clinical trials. The preferred type of clinical study to
evaluate the anti-inflammatory effect of PFS in humans was
the double-blind randomized controlled clinical trial.
Several publications reported in the present review used
randomization in clinical trials, but in a few cases, random-
ization was not described in detail or incompletely applied
(e.g., no randomization for age or gender). Positive aspects
of randomization include the elimination of biases, balanced
arms, and the capacity to form the basis for statistical tests.
A method of randomization should be considered appro-
priate if it allows each study participant to have the same
chance of receiving the intervention [22]. Methods of alloca-
tion using the date of birth or of admission, hospital numbers,
or alternation are not appropriate. Suitable methods for
randomization include using a table of random numbers or
computer generation. In most studies, the subjects enrolled
included people of both sexes. Studies of only male or female
subjects do not reflect the whole population and the results
are not reliable. Almost all studies reported the number
of dropouts, but it was not always clear if this was due
to lack of efficacy or due to adverse effects. The analytical
method used to quantify inflammatory markers such as CRP,
cytokines,malondialdehyde (MDA), and adhesionmolecules
was reported in most studies. In several cases, methods were
well described, and manufacturers’ protocols were appropri-
ate. The methods most frequently applied were the ELISA
test, immunoturbidimetry, and real-time PCR.
3.1.2. Inflammatory Biomarkers Affected by PFS in Metabolic
Syndrome. The inflammatory parameters decreasing after
PFS treatment were also reviewed. Although changes after
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PFS treatment depend on the plant used and on the bioavail-
ability of the active compounds and the method conditions,
parameters that change in a short period of time can
be selected as useful biomarkers of the anti-inflammatory
properties of PFS. In patients affected by MS (Table 1), CRP
levels decreased in three of the seven studies measuring it: a
randomized open controlled cross-over study involving 482
patients for eight weeks [18], a 10-week randomized double-
blind controlled clinical trial involving 60 patients [16], and a
1-year cross-sectional study involving 486 patients [21].
On the contrary, the other four of these studies [17, 19,
20, 23] reported no changes in CRP values. This discrepancy
could be due to the nature of the botanicals used, the
bioavailability of active compounds, the number of patients
enrolled in the study, the type of study, and/or the laboratory
methods for biomarker measurement. A larger number of
studies is necessary to assess if CRP is a suitable parameter
to evaluate the decrease of inflammatory status in MS after
treatment with PFS.
E-selectin levels were evaluated in four studies [17–19, 23],
but a decrease was recorded in only one [18], which rules
out this biomarker as suitable for the purpose. TNF-𝛼 levels
were evaluated in three studies [16, 18, 19], and two of them
[16, 18] reported a significant reduction after treatment with
soy proteins (8 weeks) and fresh algae infusion (10 weeks). No
significant differences before and after treatment with berry
derivatives were found [19]. IL-18 was evaluated in only one
study [18], and no conclusions can be drawn. IL-6 levels:
two studies [17, 23] reported no significant differences after
5 and 9 weeks; another three studies [16, 18, 20] reported a
significant reduction in both gene expression and serum after
8, 10, and 20 weeks.
We may conclude that TNF-𝛼 and IL-6 may be suitable
biomarkers to evaluate in a rather short time (6–10 weeks)
the improvement of the inflammatory status in humans after
PFS treatment, but careful consideration of the botanical for-
mulation used in the study (i.e., kind of extract, occurrence of
active principles, and their bioavailability) and the amount of
PFS taken before should be given before ruling a proinflam-
matory biomarker in or out. Additional studies are needed
before considering CRP and IL-18 as biomarkers modulated
by PFS treatment, since the data occurring in the literature
do not allow us to draw clear conclusions. The importance
of IL-6, TNF-𝛼, and CRP as proinflammatory biomarkers is
well documented. TNF-𝛼 is released by adipose tissue and is
overexpressed in obesity, and TNF-𝛼 can modulate insulin
resistance in a variety of clinical trials related to obesity [6,
15, 24]. CRP and IL-6 are peripheral inflammatory markers,
and their measurement improves the prediction of the risk of
cardiovascular events [24].
3.2. Diabetes Studies
3.2.1. In Vitro Methods. Table 2 reports the in vitro methods
applied to investigate inflammatory markers in diabetes.
The method mostly used for the assessment of beneficial
effects of botanicals/plant food supplements on diabetes
were based on quantitative PCR (qPCR), a real-time PCR
coupled with reverse transcriptase. This is a very sensitive
and specific method for analyzing mRNA levels as a marker
of gene expression. Uemura et al. [25] reported the use
of SYBR Green assay, while Chuang et al. [26, 27] and
Cao et al. [28] reported the use of the highly specific and
sensitiveTaQman assay. Other frequently used methods are
ELISA assay, immunoblotting, and transfections, in a variety
of cell cultures, with a plasmid containing the luciferase
reporter gene under the control of the NF-𝜅B responsive
element(pNF-𝜅B-luc); the latter method is widely used for
in vitro assays because it assesses events upstream of the
inflammatory cascade which activates the NF-𝜅B pathway.
In the luciferase transfection assay only, Chuang et al.
[26, 27] used primary cultures (from humans or animals) in
their experiments; they are considered the most predictive,
as primary cells retain the characteristics of the starting
tissue. However, the isolation of appropriate cells from
primary cultures can be difficult as the cell population is
heterogeneous. Moreover, primary cultures have a limited
life. Considering the challenges associated with modelling a
chronic disease such as diabetes, it is encouraging to see that
several in vitromethods for investigating inflammation have
been developed, but few of them have been applied to the
evaluation of PFS benefit assessment. In this sense, it would
be interesting to develop methods to evaluate the following
inflammatory events:
(1) nuclear translocation of NF-𝜅B factor in the nucleus
(usually evaluated by ELISA test) and the consequent
transcription of inflammatory genes and the expres-
sion of adhesion molecules on endothelium, leading
to the vascular complications of diabetes;
(2) expression of adhesion molecules (i.e., sICAM-1,
sICAM-2 and sVCAM-1, and E-selectin), which are
typically overexpressed in diabetes and in cardio-
vascular disease [38]. Adhesion molecule expression
is usually measured by RT-PCR (mRNA levels) and
ELISA (protein expression on the cell surface);
(3) evaluation ofmetalloproteinase-9 (MMP-9) secretion
and gene expression. MMP-9 is induced by hyper-
glycemia and accelerates some diabetic complications
such as retinopathy [39]. MMP-9 gene expression is
usually measured by RT-PCR, secretion and enzy-
matic activities by zymography or western blotting;
(4) evaluation of monocyte-macrophage chemotaxis
in the endothelium. Indeed, monocytes and
macrophages play a role in accelerating diabetes
and in the development of atherosclerosis. They
express specific receptors for advanced glycation
end products (AGEs), which are proteins or lipids
that become nonenzymatically glycated and oxidized
after contact with aldose sugars.
After the binding of AGEs and intracellular process-
ing, monocytes/macrophages synthesize and secrete growth-
promoting cytokines such as TNF-𝛼, interleukin 1, and
insulin-like growth factor, responsible for vascular com-
plications in diabetes [40]. Furthermore, circulating AGEs
may interact with endothelial receptors, which leads to
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perturbation of cellular properties, such as upregulation of
the transcription and the translocation of nuclear factor NF-
𝜅B [41]. Chemotaxis is generally measured under agarose
[42, 43] or by chemotaxis assay, based on evaluation of cell
migration through apposite filters after inflammatory stimuli
have been placed in chambers (BoydenChamber Assay) [44].
3.2.2. In Vivo Methods. Table 3 reports the in vivo methods
developed for human trials.
The majority of clinical trials evaluating the effect of
botanicals on inflammatory biomarkers in diabetic patients
were randomized, double-blind randomized controlled trials
and randomized, open and controlled studies. The lack of
blinding is particularly critical when the treatment is applied
versus placebo. In fact, the placebo effect is a major cause of
bias due to patient or doctor awareness [22]. Several studies
have indicated that nonrandomized trials are more likely
to yield a positive result for a new treatment than for an
established conventional one. In some of the clinical trials
considered, randomization was not described in detail or was
unsuitable. In two papers [53, 54], the number of subjects was
limited. In some studies [49, 51, 55], the dropout rate and the
reasons for it were not critically discussed. The most often
usedmethods for biomarker quantification were ELISA assay
and HPLC analysis.
3.2.3. Inflammatory Biomarkers Affected by PFS in Diabetes.
The parameters most frequently measured in clinical trials
were as follows: CRP = MDA > endothelin-1 = urinary
thromboxane B
2
metabolites > IL-6, IL-18, TNF-𝛼, and PGI
2
,
8-isoprostane. Six studies [31, 47–50, 55] examined CRP
levels; among them, three [31, 47, 50] reported a significant
reduction in serum CRP levels after 4 weeks of treatment,
two studies reported no significant changes [48, 49], and one
reported increased levels of CRP [55]. As for MS, further
studies are mandatory before conclusions on the efficacy of
in vivoCRPmeasurement in diabetes after PFS treatment can
be drawn.
Serum levels of malondialdehyde (MDA) were measured
in three studies [46, 50, 56], and all reported a significant
reduction after 4, 8, and 12 weeks of PFS consumption. MDA
is an important biomarker of oxidative stress in diabetes as
a consequence of persistent hyperglycemia and lipid perox-
idation. These trials establish serum MDA measurement as
appropriate for the purpose.
IL-6 levels weremeasured in three studies [48, 49, 56] and
one reported a significant reduction after PFS treatment [56].
IL-18 [48] and TNF-𝛼 [56] each were measured in only one
study, and in both cases, a significant decrease was found.
Nevertheless, further studies are needed to evaluate IL-6
and IL-18 as suitable inflammatory parameters. Endothelin-
1, generally overexpressed in diabetes models [57], was found
to decrease in two studies [45, 56], after 12 and 8 weeks of
treatment, respectively.
Two studies showed a significant reduction of thrombox-
ane B
2
(TXB
2
) urinary metabolites after 4 and 12 weeks of
treatment, respectively [51, 54]. PGI
2
[51] and 8-isoprostane
[48] were each evaluated only in one study; both decreased
after PFS treatment.TXB
2
, PGI
2
, and 8-isoprostane are key
proinflammatory biomarkers in diabetes. They are massively
released in the wake of hypercoagulation and the vascular
modifications that are typical for this disease. The paucity of
studies in which these mediators were assayed in response to
PFS treatment does not allow us to establish their usefulness
in investigating the benefit of PFS treatment.
4. Conclusions
The aim of the present paper was to collect and critically
discuss the existing experimental approaches used in vitro,
in silico, and in vivo for benefit assessment of botanicals or
plant food supplements (PFSs) in decreasing inflammation in
MS-related diseases. PFS often consist of a complex mixture
of compounds, which makes benefit assessment difficult and
subject to interferences and false positives. The development
of reliable methods for evaluating benefit assessment and
their application and validation is therefore crucial.
No in silico methods were found in MS-related diseases.
qRT-PCR was the in vitro method most widely applied
for measuring the expression of inflammatory cytokines in
diabetes, but no in vitromethods were found for testing PFS
benefits in MS. Data from the in vivo studies (clinical trials)
show that the inflammatory markers CRP, MDA, and PGI
2
are likely to be useful in judging the efficacy of PFS treatment,
although more studies are needed to validate this conclusion.
In addition, twoproinflammatory biomarkers, IL-6 andTNF-
𝛼, were the only two parameters to change in both in vitro
and in vivo systems, and these biomarkers should be carefully
considered in future studies.
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